VivoSim LabsFRA:4OR 38 Earnings Yield (Joel Greenblatt) % is -120.48% as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €11.84. The stock has 4 warning signs investors should review. Among 1,336 Biotechnology companies, VivoSim Labs ranks worse than 74850.22% on this metric.
VivoSim Labs's Enterprise Value for the quarter that ended in Dec. 2025 was €5.94 Mil.
VivoSim Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.58 Mil. VivoSim Labs's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -120.48%.
The historical rank and industry rank for VivoSim Labs's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:4OR'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5130.15 Med: -48.07 Max: 2479
Current: 84.03
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of VivoSim Labs was 2479.00%. The lowest was -5130.15%. And the median was -48.07%.
FRA:4OR's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -9.745
vs FRA:4OR: 84.03
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. VivoSim Labs's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
VivoSim Labs Earnings Yield (Joel Greenblatt) % Related Terms
VivoSim Labs Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
VivoSim Labss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2025 is calculated as
VivoSim Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.58 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -120.48% mean?
VivoSim Labs (FRA:4OR) has a Earnings Yield (Joel Greenblatt) % of -120.48% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #999999 out of 1336 companies in the Biotechnology industry.
Is VivoSim Labs' Earnings Yield (Joel Greenblatt) % too high?
VivoSim Labs' current Earnings Yield (Joel Greenblatt) % is -120.48%. Based on the distribution chart, VivoSim Labs ranks #999999 out of 1336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Earnings Yield (Joel Greenblatt) % compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #999999 out of 1336 companies for Earnings Yield (Joel Greenblatt) %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Earnings Yield (Joel Greenblatt) % is -120.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Earnings Yield (Joel Greenblatt) % of -120.48%. The stock's GF Value™ is €11.84, compared to a current price of €3.49 — trading 70.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -120.48%. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Earnings Yield (Joel Greenblatt) % is -120.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 70.5% below its estimated GF Value™ of €11.84.
Key valuation signals for FRA:4OR:
Earnings Yield (Joel Greenblatt) %: -120.48%
GF Value™: €11.84 vs. price of €3.49 (70.5% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
